Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: Lipid-lowering therapies - an industry perspective

被引：2

作者：

Jackson, JD ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Outcomes Res, Princeton, NJ 08543 USA

来源：

AMERICAN HEART JOURNAL | 1999年 / 137卷 / 05期

关键词：

D O I：

10.1016/S0002-8703(99)70441-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S105 / S110

页数：6

共 53 条

[1] AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS [J].

ANDERSON, KM ;

WILSON, PWF ;

ODELL, PM ;

KANNEL, WB .

CIRCULATION, 1991, 83 (01) :356-362

[2] Cost-effectiveness of Pravastatin in secondary prevention of coronary artery disease [J].

Ashraf, T ;

Hay, JW ;

Pitt, B ;

Wittels, E ;

Crouse, J ;

Davidson, M ;

Furberg, CD ;

Radican, L .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04) :409-414

[3] DRUG REGULATION AND DRUG INFORMATION - WHO SHOULD DO WHAT TO WHOM [J].

AVORN, J .

AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (01) :18-19

[4] RHABDOMOLYSIS WITH SIMVASTATIN USE [J].

BERLAND, Y ;

COPANAT, HV ;

DURAND, C ;

BAZ, M ;

LAUGIER, R ;

MUSSO, JL .

NEPHRON, 1991, 57 (03) :365-366

[5]

BIZZARO N, 1992, CLIN CHEM, V38, P1504

[6] REDUCTION IN CARDIOVASCULAR EVENTS DURING PRAVASTATIN THERAPY - POOLED ANALYSIS OF CLINICAL EVENTS OF THE PRAVASTATIN ATHEROSCLEROSIS INTERVENTION PROGRAM [J].

BYINGTON, RP ;

JUKEMA, JW ;

SALONEN, JT ;

PITT, B ;

BRUSCHKE, AV ;

HOEN, H ;

FURBERG, CD ;

MANCINI, J .

CIRCULATION, 1995, 92 (09) :2419-2425

[7]

Campeau L, 1997, NEW ENGL J MED, V336, P153

[8]

*CAN WHEAT BOARD, 1994, GRAIN MATT, P2

[9] The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin [J].

Caro, J ;

Klittich, W ;

McGuire, A ;

Ford, J ;

Norrie, J ;

Pettitt, D ;

McMurray, J ;

Shepherd, J .

BRITISH MEDICAL JOURNAL, 1997, 315 (7122) :1577-1582

[10]

CARO JJ, 1998, PHARMACOEPIDEM DR S, V7, pS89

← 1 2 3 4 5 6 →